Citigroup’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-212,510
| Closed | -$4.13M | – | 7895 |
|
|
2018
Q1 | $4.13M | Buy |
212,510
+175,616
| +476% | +$3.45M | ﹤0.01% | 1936 |
|
|
2017
Q4 | $614K | Buy |
36,894
+36,402
| +7,399% | +$667K | ﹤0.01% | 3889 |
|
|
2017
Q3 | $10K | Sell |
492
-1,051
| -68% | -$20.1K | ﹤0.01% | 6711 |
|
|
2017
Q2 | $25K | Sell |
1,543
-2,856
| -65% | -$42.2K | ﹤0.01% | 6184 |
|
|
2017
Q1 | $56K | Sell |
4,399
-157,146
| -97% | -$1.9M | ﹤0.01% | 5621 |
|
|
2016
Q4 | $2.14M | Buy |
161,545
+158,380
| +5,004% | +$2.71M | ﹤0.01% | 2859 |
|
|
2016
Q3 | $75K | Sell |
3,165
-30,817
| -91% | -$828K | ﹤0.01% | 5407 |
|
|
2016
Q2 | $980K | Sell |
33,982
-19,637
| -37% | -$640K | ﹤0.01% | 2989 |
|
|
2016
Q1 | $1.72M | Buy |
53,619
+49,375
| +1,163% | +$1.74M | ﹤0.01% | 2685 |
|
|
2015
Q4 | $181K | Sell |
4,244
-2,476
| -37% | -$98.9K | ﹤0.01% | 4842 |
|
|
2015
Q3 | $236K | Sell |
6,720
-2,029
| -23% | -$91.4K | ﹤0.01% | 4370 |
|
|
2015
Q2 | $402K | Sell |
8,749
-1,779
| -17% | -$84.4K | ﹤0.01% | 3909 |
|
|
2015
Q1 | $494K | Sell |
10,528
-12,684
| -55% | -$505K | ﹤0.01% | 3757 |
|
|
2014
Q4 | $735K | Buy |
23,212
+9,801
| +73% | +$287K | ﹤0.01% | 3460 |
|
|
2014
Q3 | $318K | Buy |
13,411
+3,978
| +42% | +$102K | ﹤0.01% | 3884 |
|
|
2014
Q2 | $283K | Sell |
9,433
-1,942
| -17% | -$52.4K | ﹤0.01% | 3847 |
|
|
2014
Q1 | $300K | Sell |
11,375
-26,270
| -70% | -$657K | ﹤0.01% | 3949 |
|
|
2013
Q4 | $947K | Buy |
37,645
+11,655
| +45% | +$260K | ﹤0.01% | 3238 |
|
|
2013
Q3 | $533K | Sell |
25,990
-6,630
| -20% | -$137K | ﹤0.01% | 3391 |
|
|
2013
Q2 | $650K | Buy |
+32,620
| New | +$579K | ﹤0.01% | 3255 |
|
Citigroup's IPXL Position: Q2 2018 in Review
Citigroup sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 212,510 shares — an estimated $4.13M sold.
Citigroup first reported a position in IPXL in Q2 2013 and held it in 20 quarters. The position peaked at $4.13M in Q1 2018. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- Citigroup reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- Citigroup sold 212,510 Impax Laboratories, Inc. shares in Q2 2018, an estimated $4.13M.
- Citigroup first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 20 quarters.
- Citigroup's Impax Laboratories, Inc. position peaked at $4.13M in Q1 2018.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on Citigroup's 13F filing for Q2 2018, filed 10 Aug 2018.